Clinical Trial Update: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating encorafenib with cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with BRAF V600E-mutant metastatic col…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Cetuximab (cetuximab)
• Encorafenib (encorafenib)
• Folinic acid (folinic acid)
• Irinotecan (Irinotecan)

Snippet

Sponsor: Pierre Fabre Medicament | Conditions: BRAF V600E, Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED